Clinicogenomics

Guide Early Discovery for Clinical Development

Enrich real-world oncology patient data with comprehensive genomic profiling information to discover hidden patterns and inform early-stage drug discovery research.

Group 48
Use Cases

Future-Plan for Clinical Research and Development

Clinicogenomics is an optional add-on designed to enrich our robust oncology patient data with genomic markers to help generate insights about new research and development opportunities.

Genomic Data Includes:

Group 213

COTA by the Numbers

2.1M+ Cancer Patient Lives

50/50 Academic vs. Community Treatment Setting

3 Approvals Supported

9 Hematology and Solid Tumor Diagnoses

5-Year Average Follow-up

2X Higher Inclusion Percentage in ECA vs. Competitor

Group 203
Additional Support

Get the Most of Your Clinicogenomics Data with Real-World Insights and Support

Real-World Support gives you access to industry veterans who can help you structure study designs, provide guidance on protocol and analysis,
make recommendations for regulatory submission packets, review research and manuscripts, and more to ensure your research achieves the highest quality standards.

Resources

Fueling the Future of Cancer Research

Explore our collection of clinical research, recent press, podcasts, and more.

Four Ways Pharmaceutical Companies Are De-Risking R&D with Real-World Data

Four Ways Pharmaceutical Companies Are De-Risking R&D with Real-World Data Pharmaceutical research and development is inherently complex and high-risk. Sponsors...

Sounds of Support: COTA & Friends Unite for Young Adults with Cancer

Cancer affects everyone, including adolescents and young adults who are at increasing risk of developing certain types of disease. It’s...

Extending COTA’s global reach with RWD in oncology research

Cancer is a disease that respects no borders: it affects everyone around the world, no matter where they live.  The...

Find Your Next Breakthrough

Discover the power of real world cancer data to help you understand patient journeys across the oncology spectrum and inform research directions.
Group 11